Johnson Financial Group Inc. boosted its holdings in Gilead Sciences (NASDAQ:GILD) by 14.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,702 shares of the biopharmaceutical company’s stock after buying an additional 6,207 shares during the quarter. Johnson Financial Group Inc.’s holdings in Gilead Sciences were worth $3,672,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of GILD. Wealthcare Advisory Partners LLC acquired a new stake in Gilead Sciences during the 3rd quarter valued at approximately $133,000. Certified Advisory Corp acquired a new stake in Gilead Sciences during the 4th quarter valued at approximately $133,000. Advisors Preferred LLC acquired a new stake in Gilead Sciences during the 1st quarter valued at approximately $140,000. Horan Capital Advisors LLC. acquired a new stake in Gilead Sciences during the 3rd quarter valued at approximately $144,000. Finally, Mckinley Capital Management LLC Delaware increased its position in Gilead Sciences by 67.7% during the 1st quarter. Mckinley Capital Management LLC Delaware now owns 2,130 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 860 shares during the period. Institutional investors and hedge funds own 78.16% of the company’s stock.
In related news, EVP Gregg H. Alton sold 14,435 shares of Gilead Sciences stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $81.54, for a total value of $1,177,029.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robin L. Washington sold 5,000 shares of Gilead Sciences stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total transaction of $401,550.00. Following the completion of the sale, the chief financial officer now directly owns 23,749 shares of the company’s stock, valued at approximately $1,907,282.19. The disclosure for this sale can be found here. In the last three months, insiders sold 241,102 shares of company stock valued at $18,237,884. 1.30% of the stock is currently owned by insiders.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.67 by ($0.19). Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The business had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.40 billion. During the same period in the previous year, the business posted $2.23 EPS. The business’s revenue for the quarter was down 21.8% compared to the same quarter last year. sell-side analysts expect that Gilead Sciences will post 5.75 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 28th. Investors of record on Friday, June 15th will be given a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 3.37%. The ex-dividend date of this dividend is Thursday, June 14th. Gilead Sciences’s payout ratio is currently 26.64%.
A number of analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, May 7th. BidaskClub downgraded shares of Gilead Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, May 4th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 2nd. Morgan Stanley decreased their target price on shares of Gilead Sciences from $85.00 to $81.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 2nd. Finally, Barclays decreased their target price on shares of Gilead Sciences from $95.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, ten have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $88.14.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.